Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925950 · ClinicalTrials.gov registry record · Phase 2
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
A Phase 2 study, sponsored by Soligenix.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01925950 is a Phase 2 study that was terminated before completion, run by Soligenix. The registered enrollment target is 2 participants.
The verdict
NCT01925950, a Phase 2 study, was terminated before completion, sponsored by Soligenix.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
Interventions
- DRUG Placebo
- DRUG orBec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925950
The ClinicalTrials.gov registry entry for NCT01925950 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01925950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925950 about?
NCT01925950 is a clinical study titled "Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)". Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
What is the current status of trial NCT01925950?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-12. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01925950?
The interventions under investigation include: Placebo (DRUG), orBec (DRUG).
Who is sponsoring clinical trial NCT01925950?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.